Abstract: Methods of treating a head and neck cancer are disclosed.

Abstract: A method and an apparatus are provided for building a subject-specific statistical model of shape variation for an anatomical structure using a set of geometric representations of shape for the anatomical structure. Each representation is associated with one of multiple subjects, each subject having a respective subset of associated representations, and each subset comprising multiple representations including a reference representation. The multiple representations correspond to different shapes of the anatomical structure arising from physical motion and/or deformation thereof. The method comprises specifying a set of shape parameters whose values, for any given representation, characterise the shape of the representation, and for each subject, representing a probability distribution of the values of the shape parameters across the subset of representations associated with that subject by a set of subject-specific distribution parameters.

Abstract: The present invention provides a variant proliferation-inducing ligand (APRIL), which has a higher binding affinity to BCMA than wild-type APRIL; and/or altered binding kinetics compared with wild-type APRIL, and/or a higher BCMA:TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) binding ratio than wild-type APRIL and which comprises mutations at one or more of the following positions: A125, V174, T175, M200, P201, S202, H203, D205 and R206.

Abstract: A method and apparatus are provided for calibrating a wireless access point comprising an array of multiple (m) antennas denoted Ai (i=1 . . . m), each antenna having a respective internal phase offset ?i. The method comprises receiving a signal from at least one transmitter located at a substantially known bearing from the wireless access point. The method further comprises determining an estimated value for each internal phase offseti such that an angle of arrival (AoA) spectrum calculated for the received signal on the basis of said estimated values matches the known bearing, wherein said AoA spectrum is calculated by treating said multiple antennas as a phased array. A method and an apparatus are also provided for calibrating a wireless access point comprising first and second arrays of multiple antennas, each antenna array having a respective radio unit, and each antenna in an array having a respective internal phase offseti.

Abstract: The present invention concerns peptides comprising at least one motif having the amino acid sequence B1-X3-10-B2, wherein B1 and B2 are identical or different and each is a basic amino acid and X3-10 is a sequence of 3 to 10 identical or different non-acidic amino acids, and wherein the N-terminus of the peptide comprises a D-amino acid and/or includes a protecting group, collagen or hyaluronic acid conjugates comprising the same peptides and a therapeutic or diagnostic agent, and compositions and uses thereof. It also concerns peptides comprising at least one motif having the amino acid sequence B1-X3-10-B2, wherein B1 and B2 are identical or different and each is a basic amino acid and X3-10 is a sequence of 3 to 10 identical or different non-acidic amino acids, for use in the treatment or prevention of ocular diseases or conditions.

Abstract: A method and apparatus are provided for determining the location of a mobile device using multiple wireless access points, each wireless access point comprising multiple antennas. The method comprises receiving a communication signal from the mobile device at said multiple antennas of said multiple wireless access points. For each wireless access point, angle-of-arrival information of the received communication signal at the wireless access point is determined, based on a difference in phase of the received signal between different antennas. The determined angle-of-arrival information for the received communication signal from the mobile device is then collected from each of the multiple wireless access points, and the location of the mobile device is estimated from the collected angle-of-arrival information. The determining of the angle-of-arrival information for a wireless access point includes compensating for a non-zero elevation of the mobile device with respect to the wireless access point.

Abstract: The invention relates to methods for attaching therapeutic agents to structures produced by thermally induced phase separation as well as methods for coating devices and producing multi-layered microspheres.

Abstract: A method and an apparatus are provided for performing passing sensing using wireless digital communications. The wireless digital communications are frame-based with a predefined frame structure. The method includes receiving a reference signal into to a reference channel, wherein the reference signal comprises a direct version of a radio frequency transmission as part of said wireless digital communications; receiving a surveillance signal into a surveillance channel; detecting and extracting portions of the reference signal corresponding to data transmissions based on said predefined frame structure; extracting portions of the surveillance signal corresponding to the extracted portions of the reference signal; performing a cross-correlation on the extracted portions of the reference signal and the surveillance signal to determine a range-Doppler surface; and providing a real-time display of said range-Doppler surface and/or of information derived therefrom.

Abstract: The invention provides a method of preparing a suspension of microbubbles for use in a carrier liquid, wherein the microbubbles have a gas core and a liquid shell, said liquid shell comprising magnetic nanoparticles, and wherein the microbubbles satisfy the following conditions: (i) the force due to buoyancy (FBW) of the microbubble in the carrier liquid is greater than the weight (W) of the microbubble; (ii) the magnetic force (FM) on the microbubble due to a magnetic field applied to the carrier liquid is greater than the combined weight (W) and force due to buoyancy (FBW) of the microbubble; (iii) said magnetic force (FM) on the microbubble is greater than the force due to viscous drag (FD) on the microbubble due to flow of the carrier liquid; and (iv) the scattering cross section (?scat) of the microbubble to ultrasound allows the microbubble to be detectable and rupturable on exposure to ultrasound.

Abstract: Methods of treating a head and neck cancer are disclosed.

Abstract: Methods, systems and apparatus for manipulating electromagnetic radiation such as laser beams include a first acousto-optic deflector optimised for efficient transmission at the input beam angle and a second acousto-optic deflector of lower peak efficiency than the first acousto-optic deflector but which accepts beams from a wider range of angles at better transmission efficiency than the first acousto-optic deflector by passing a beam optimised for efficient transmission through the first acousto-optic deflector at the input beam angle, deflecting the beam using the first acousto-optic deflector, passing the deflected beam through the second acousto-optic deflector, which has a lower peak efficiency than the first acousto-optic deflector and accepts beams from a wider range of angles at better transmission efficiency than the first acousto-optic deflector, and deflecting the beam using the second acousto-optic deflector.

Abstract: The present invention relates to the use of a compound containing a moiety of formula (I) as a reagent for linking a compound of formula R1—H which comprises a first functional moiety of formula F1 to a second functional moiety of formula F2 wherein X, X?, Y, R1, F1 and F2 are as defined herein. The present invention also provides related processes and products. The present invention is useful for creating functional conjugate compounds, and specifically conjugates in which at least one of the constituent molecules carries a thiol group.

Abstract: A method for dispersing nanotubes, comprising contacting the nanotubes with an electronic liquid comprising a metal and an amine solvent, a solution of dispersed nanotubes, comprising individual nanotubes at a concentration of greater than about 0.01 mgml?1 and a solvent and a nanotube crystal comprising a close packed array of nanotubes, wherein the crystal has a thickness of 100 nm or more are described.

Abstract: The present invention relates to the use of a compound containing a moiety of formula (I) as a reagent for linking a compound of formula R1—H which comprises a first functional moiety of formula F1 to a second functional moiety of formula F2 wherein X, X?, Y, R1, F1 and F2 are as defined herein. The present invention also provides related processes and products. The present invention is useful for creating functional conjugate compounds, and specifically conjugates in which at least one of the constituent molecules carries a thiol group.

Abstract: A method for producing a solution of dispersed graphenes comprising contacting graphite having a dimension in the a-b plane of 10 ?m or less with an electronic liquid comprising a metal and a polar aprotic solvent, and solutions of dispersed graphenes which may be obtained by such a method are described.

Abstract: The invention relates to liver damage, and to pharmaceutical compositions for use in treating, preventing or ameliorating liver damage or disease, especially acute liver damage. The invention is particularly, although not exclusively, concerned with treating or preventing liver damage caused by paracetamol poisoning. The invention also extends to methods of treating such conditions.

Abstract: A solid, compressed pharmaceutical composition comprises i) a peptide active pharmaceutical ingredient, ii) a polysaccharide excipient and/or an albumin, and iii) an oligosaccharide excipient. The polysaccharide excipient may be hyaluronic acid, or the potassium salt thereof, and the oligosaccharide excipient may be trehalose.

Abstract: The present invention provides a reproducible preliminary in-situ oxide removal step for patterned self-assisted III-V semiconductor nanowire growth. Here “in-situ” means located within the same treatment environment or apparatus as the nanowire growth process, e.g. with a molecular beam epitaxy (MBE) apparatus or the like. Providing an in-situ process may prevent the formation of a thin oxide layer during transfer of the substrate into the nanowire growth apparatus.